Navigation Links
Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Date:5/27/2009

SAN DIEGO, May 27 /PRNewswire/ -- Verus Pharmaceuticals, Inc. ("Verus"), a specialty pharmaceutical company, announced today that it has filed a lawsuit against AstraZeneca AB ("AstraZeneca") and Tika Lakemedel AB ("Tika") in the Supreme Court of the State of New York, in which it is seeking $1.3 billion on claims of fraud, breach of contract, and conversion. Verus claims that AstraZeneca and its wholly owned subsidiary Tika disregarded their obligations under three agreements with Verus, entered into in 2007, pursuant to which the defendants were to pursue the research and development of Verus' assets, including budesonide, a steroid for the treatment of pediatric asthma in the United States. Verus further alleges that defendants' representations that induced Verus to enter into the agreements constituted fraud.

About Verus

Verus is dedicated to improving the lives of children and those who care for them. More information about Verus is available on the company's corporate website at www.veruspharm.com.

Verus(R) is a registered trademark of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company Contact:
    Blair C. Fensterstock, Esq.,
    Managing Director
    Fensterstock & Partners LLP
    BFensterstock@fensterstock.com
    212-785-4100 Office; 917-689-1137 Cell


'/>"/>
SOURCE Verus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adolescent Growth Plate Injuries May Be Related to Overuse
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals: Risks of Overusing Antibiotics
3. Kids Overuse Sports Injuries Are on the Rise
4. Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment?
5. Urgent need for research into the best treatment for medication overuse headaches
6. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
7. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
8. ReachMD and VerusMed Broadcast Medical Conference Coverage on XM Satellite Radio
9. Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
10. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
11. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: ... of Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor ... holds a bachelor degree in religious education and a master degree in theology. , ...
(Date:1/24/2017)... ... 23, 2017 , ... OSF Ventures, the corporate investment arm ... platform headquartered in Silicon Valley that connects startups to corporations and invests in ... three-year agreement to be a corporate sponsor of Plug and Play’s program for ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s ... all people and by all people shines as a bright beacon of determination ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... translation and localization services for life science companies, has achieved ISO 17100:2015 ... TÜV SÜD America. ISO 17100 is the globally recognized standard that establishes ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 7D Surgical announced today that ... U.S. Food and Drug Administration (FDA) and a ... North American commercial launch of its innovative Machine-vision ... the 7D Surgical System.  The ... and machine vision algorithms to eliminate the long-standing ...
(Date:1/23/2017)... and Markets has announced the addition of the "Needle Free Drug ... report to their offering. ... Highlights: The report provides a detailed analysis ... Market forecasts till 2025, using estimated market values as the ... Regions and Countries Key developments and strategies observed in ...
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
Breaking Medicine Technology: